This page contains a Flash digital edition of a book.
CCVI in MS—A Medical, Sociological, and Media Controversy


to demand it where it was not readily available, again particularly in Canada. The controversy and dialogue spread rapidly through the social media, with numerous reports of subjective symptomatic improvement by individuals with MS who had undergone the procedure.


Skepticism in the Scientific Community


The initial Zamboni reports were met with considerable skepticism by most of the MS scientific and professional community. Like any scientific observation, the validity of the CCSVI association with MS required confirmation. Soon after the initial publications, MS experts, as well as others, began to point out numerous flaws in the Zamboni methodology, as well as citing evidence that questioned the biologic plausibility of the CCSVI hypothesis. This initial incredulity was undoubtedly heightened by the claims of 100 % correspondence between CCSVI and MS, as rarely, if ever, do biologic phenomena occur in an all-or-none fashion. The critiques have noted that the normal human venous anatomy is highly variable and not well-defined and that the venous drainage of the brain is highly flexible and redundant, as well as posture-dependent. No previous descriptions of CCSVI have appeared; blockage of internal jugular veins (IJVs) has never before been associated with MS; and head and neck surgeons not uncommonly tie off either or both IJVs without deleterious effect. Furthermore, MS patients have neither clinical nor radiologic findings consistent with increased venous pressure.


From a methodologic perspective, critics have emphasized that the technician in the Zamboni study was unblinded and that the ultrasound procedure is very operator-dependent. In the treatment study, which was conducted at a single center, no control group with sham procedure was included and the study was non-randomized. Zamboni et al. themselves noted no benefit in patients with progressive disease and observed a 47 % restenosis rate in treated IJVs.


No Replication of Zamboni Results


What about attempts to replicate the Zamboni observations and to investigate the possibility of venous abnormalities in MS patients through methodologies other than ultrasound alone? To date, no published series has even approached the Zamboni results in terms of sensitivity or specificity. In the largest series reported to date, including 499 subjects (289 with MS), Zivadinov et al found evidence for CCSVI in 56.1 % of MS patients and only 38.1 % of subjects with clinically isolated syndrome, compared to an occurrence in 22.7 % of healthy control subjects and 42.5 % of those with other neurologic diseases.3


Sundström et al.,5


Additional small ultrasound series by Doepp et al.,4 and Wattjes et al.6


failed to find any support for the


Zamboni hypothesis. In a subsequent study using magnetic resonance venography Doepp et al., also failed to substantiate CCSVI.7 Nonetheless, a recent meta-analysis by Laupacis et al.8


found that the


published data did suggest the possibility of an association between CCSVI and MS. However, the authors emphasized that no definitive conclusions could be drawn because the cited studies were too heterogenous in their inclusion criteria and methodology and they lacked adequate blinding. Subsequent to the publication of the meta-analysis, among numerous additional presentations at the large international meeting of the European Committee for Treatment and Research in Multiple Sclerosis/Americas Committee for


US NEUROLOGY


Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS) in Amsterdam in October 2011, nearly all failed to provide support for venous insufficiency in MS.


The skepticism of the scientific community about CCSVI, juxtaposed to the relentless clamor of the MS patient community for trials of CCSVI (or even to make the procedure generally available), has created an inevitable tension and a conundrum for funding agencies. In 2010, the National Multiple Sclerosis Society, along with the Multiple Sclerosis Society of Canada, reached the conclusion that the CCSVI hypothesis required further investigation, and committed $2.4 million to fund seven North American studies aimed at replicating the Zamboni findings, as well as exploring other ways to elucidate the status of the venous system in people with MS, and also to look at people at early stages of MS (or even children) who would be expected to be affected if CCSVI plays a causative role in MS. In addition, the Italian MS Society also funded a large ultrasound study, whose preliminary results presented in Amsterdam in October 2011 failed to substantiate the Zamboni claims.


Canadian Institutes of Health Research Announcement of Phase I/II Trials


The announcement was made despite an earlier statement by Alain Beaudet, President of the CIHR in August 2010, following a meeting of a multidisciplinary scientific working group on CCSVI, that noted: “In the absence of clear and convincing evidence for CCSVI, the performance of an interventional venoplasty trial with its attendant risk to MS patients is not appropriate at this time. It is unlikely that a proposal… would pass a peer review panel because evidence that CCSVI exists is currently lacking. Similarly there are serious ethical issues associated with doing such a trial given the lack of convincing evidence for CCSVI.” It is difficult to understand from a purely scientific perspective the justification for undertaking a therapeutic trial at this time in view of the fact that the preponderance of evidence that has emerged since the August 2010 statement has been negative. The CIHR can muster some support for its position, from the Laupacis meta-analysis,8


Despite the reservations of much of the MS professional community, yet facing continuing political pressure, the Canadian Institutes of Health Research (CIHR) announced on November 25, 2011 that it would issue a request for proposals (RFP) for a Phase I/II clinical trial of cerebral venoplasty in MS.9


requested


by the Institute, which found “a markedly higher prevalence of CCSVI in MS patients compared to HC [healthy controls] that was statistically significant, even when a ‘conservative’ analysis was conducted”, albeit noting that “the results do not allow definitive conclusions to be reached.” The announcement of the RFP, undoubtedly influenced by intense patient and political pressure in Canada, is tempered by its final statement emphasizing that any such proposed trial will have to pass scrutiny of institutional review boards whose approval seems far from certain at this time.


Significance of Canadian Institutes of Health Research Announcement in Public Domain One thing is certain, however. That is the clear recognition that CCSVI has been a medical/sociologic phenomenon of immense magnitude in the MS patient and professional community. A variety of factors coalesced to create the “perfect storm”. A patient population with a (potentially) serious illness existed and those affected, already often


85


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108